Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MD.0000000000001293 http://scihub22266oqcxt.onion/10.1097/MD.0000000000001293 C4616615!4616615 !26252306     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 249.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26252306 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Medicine+(Baltimore) 2015 ; 94 (31 ): e1293 Nephropedia Template TP {{tp|p=26252306 |t=2015. A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease |pdf=|usr=}}{{26252306 }} gab.com Text A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease JO: Medicine (Baltimore) http://www.kidney.de/pget.php?&tw=1&pmid=26252306 #FOAvip Effect of aspirin (antiplatelet agents) in patients with peripheral artery disease (PAD) was still controversial. Varying studies reported varying results. Therefore, we did this meta-analysis to investigate if aspirin could reduce cardiovascular events in patients with PAD.A comprehensive literature search (PubMed, CCTR, Embase, Web of Science, CNKI, CBM-disc, and relevant websites) was conducted from 1990 to September 2014. The key search terms ("aspirin," "PAD," "peripheral arterial occlusive diseases," and "claudication") produced 9 high-quality randomized controlled trials (RCTs) of aspirin versus placebo/control. Mantel-Haenszel random-effects model was used to analysis of the 9 RCTs. The primary outcome was the cardiovascular events.Nine RCTs, composed of 9526 patients (4786 aspirin-treated and 4740 placebo or control-treated patients), were meta-analyzed. The results indicated that compared to placebo/control, aspirin could not significantly reduce the cardiovascular events (OR?=?0.81, 95% CI?=?0.56-1.15). Moreover, aspirin could not produce better effect on prevention of nonfatal myocardial infarction (OR?=?0.98, 95% CI?=?0.52-1.84), nonfatal stroke (OR?=?0.89, 95% CI?=?0.69-1.14), cardiovascular death (OR?=?0.97, 95% CI?=?0.68-1.38), any death (OR?=?1.05, 95% CI?=?0.85-1.30), and major bleeding (OR?=?1.16, 95% CI?=?0.82-1.65) than placebo/control. But aspirin, as monotherapy therapy, did significantly reduce the risk of nonfatal stroke (OR?=?0.42, 95% CI?=?0.21-0.84).Aspirin, as monotherapy or combination therapy, did not result in a significant decrease in the cardiovascular events. But aspirin, as monotherapy therapy, did significantly reduce the risk of nonfatal stroke. Our conclusion might help clinicians in clinical treating PAD. Future studies are needed to draw firm conclusions about the clinical benefit and risks of aspirin and other antiplatelet agents. Twit Text FOAVip A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease ????Medicine (Baltimore) http://www.kidney.de/pget.php?&tw=1&pmid=26252306 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26252306 #FOAvip English Wikipedia <ref>{{Cite pmid|26252306 }}</ref> A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease #MMPMID26252306 Qian J ; Yang XH Medicine (Baltimore) 2015[Aug]; 94 (31 ): e1293 PMID26252306 show ga Effect of aspirin (antiplatelet agents) in patients with peripheral artery disease (PAD) was still controversial. Varying studies reported varying results. Therefore, we did this meta-analysis to investigate if aspirin could reduce cardiovascular events in patients with PAD.A comprehensive literature search (PubMed, CCTR, Embase, Web of Science, CNKI, CBM-disc, and relevant websites) was conducted from 1990 to September 2014. The key search terms ("aspirin," "PAD," "peripheral arterial occlusive diseases," and "claudication") produced 9 high-quality randomized controlled trials (RCTs) of aspirin versus placebo/control. Mantel-Haenszel random-effects model was used to analysis of the 9 RCTs. The primary outcome was the cardiovascular events.Nine RCTs, composed of 9526 patients (4786 aspirin-treated and 4740 placebo or control-treated patients), were meta-analyzed. The results indicated that compared to placebo/control, aspirin could not significantly reduce the cardiovascular events (OR?=?0.81, 95% CI?=?0.56-1.15). Moreover, aspirin could not produce better effect on prevention of nonfatal myocardial infarction (OR?=?0.98, 95% CI?=?0.52-1.84), nonfatal stroke (OR?=?0.89, 95% CI?=?0.69-1.14), cardiovascular death (OR?=?0.97, 95% CI?=?0.68-1.38), any death (OR?=?1.05, 95% CI?=?0.85-1.30), and major bleeding (OR?=?1.16, 95% CI?=?0.82-1.65) than placebo/control. But aspirin, as monotherapy therapy, did significantly reduce the risk of nonfatal stroke (OR?=?0.42, 95% CI?=?0.21-0.84).Aspirin, as monotherapy or combination therapy, did not result in a significant decrease in the cardiovascular events. But aspirin, as monotherapy therapy, did significantly reduce the risk of nonfatal stroke. Our conclusion might help clinicians in clinical treating PAD. Future studies are needed to draw firm conclusions about the clinical benefit and risks of aspirin and other antiplatelet agents. |Aspirin/*therapeutic use [MESH] |Humans [MESH] |Peripheral Arterial Disease/complications/*drug therapy/mortality [MESH] |Platelet Aggregation Inhibitors/*therapeutic use [MESH]A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents(epmc).pdf DeepDyve Pubget Overpricing